Clinical Outcomes and Correlates of TP53 Mutations and Cancer
- 25 November 2009
- journal article
- review article
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Biology
- Vol. 2 (3), a001016
- https://doi.org/10.1101/cshperspect.a001016
Abstract
The initial observation that p53 accumulation might serve as a surrogate biomarker for TP53 mutation has been the cornerstone for vast translational efforts aimed at validating its clinical use for the diagnosis, prognosis, and treatment of cancer. Early on, it was realized that accurate evaluation of p53 status and function could not be achieved through protein-expression analysis only. As our understanding of the p53 pathway has evolved and more sophisticated methods for assessment of p53 functional integrity have become available, the clinical and molecular epidemiological implications of p53 abnormalities in cancers are being revealed. They include diagnostic testing for germline p53 mutations, and the assessment of selected p53 mutations as biomarkers of carcinogen exposure and cancer risk and prognosis. Here, we describe the strengths and limitations of the most frequently used techniques for determination of p53 status in tumors, as well as the most remarkable latest findings relating to its clinical and epidemiological value.Keywords
This publication has 100 references indexed in Scilit:
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Prognostic Value of Abnormal p53 Expression in Locally Advanced Prostate Cancer Treated With Androgen Deprivation and Radiotherapy: A Study Based on RTOG 9202International Journal of Radiation Oncology*Biology*Physics, 2007
- Inflammation and cancer: An ancient link with novel potentialsInternational Journal of Cancer, 2007
- Transactivation of miR-34a by p53 Broadly Influences Gene Expression and Promotes ApoptosisMolecular Cell, 2007
- A microRNA component of the p53 tumour suppressor networkNature, 2007
- Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHuman Mutation, 2007
- An overview of prognostic factors for long-term survivors of breast cancerBreast Cancer Research and Treatment, 2007
- Expression of p53 isoforms in squamous cell carcinoma of the head and neckEuropean Journal of Cancer, 2007
- Assessing TP53 status in human tumours to evaluate clinical outcomeNature Reviews Cancer, 2001
- The p53 tumour suppressor geneNature, 1991